Disease Control Priorities: Improving Health and Reducing Poverty
Disease Control Priorities: Improving Health and Reducing Poverty

EDITORS
Dean T. Jamison
Hellen Gelband
Susan Horton
Prabhat Jha
Ramanan Laxminarayan
Charles N. Mock
Rachel Nugent
Contents

Foreword by Bill and Melinda Gates  ix
Introduction by Lawrence H. Summers  xi
Preface  xv
Abbreviations  xvii

PART 1  OBJECTIVES AND CONCLUSION OF DISEASE CONTROL PRIORITIES, THIRD EDITION

1. Universal Health Coverage and Intersectoral Action for Health  3

2. Intersectoral Policy Priorities for Health  23
   David A. Watkins, Rachel Nugent, Helen Saxenian, Gavin Yamey, Kristen Danforth, Eduardo González-Pier, Charles N. Mock, Prabhat Jha, Ala Alwan, and Dean T. Jamison

3. Universal Health Coverage and Essential Packages of Care  43
   David A. Watkins, Dean T. Jamison, Anne Mills, Rifat Atun, Kristen Danforth, Amanda Glassman, Susan Horton, Prabhat Jha, Margaret E. Krug, Ole F. Norheim, Jinyuan Qi, Agnes Soucat, Stéphane Verguet, David Wilson, and Ala Alwan
PART 2 PROBLEMS AND PROGRESS

   Colin Mathers, Gretchen Stevens, Dan Hogan, Wahyu Retno Mahanani, and Jessica Ho

5. Annual Rates of Decline in Child, Maternal, Tuberculosis, and Noncommunicable Disease Mortality across 109 Low- and Middle-Income Countries from 1990 to 2015  105
   Osondu Ogbuoji, Jinyuan Qi, Zachary D. Olson, Gavin Yamey, Rachel Nagent, Ole Frithjof Norheim, Stéphane Verguet, and Dean T. Jamison

6. Economic Burden of Chronic Ill Health and Injuries for Households in Low- and Middle-Income Countries  121
   Beverley M. Essue, Tracey-Lea Laba, Felicia Knaul, Annie Chu, Hoang Van Minh, Thi Kim Phuong Nguyen, and Stephen Jan

PART 3 ECONOMIC EVALUATION RESULTS FROM DISEASE CONTROL PRIORITIES, THIRD EDITION

7. Cost-Effectiveness Analysis in Disease Control Priorities, Third Edition  147
   Susan Horton

   Stéphane Verguet and Dean T. Jamison

   Angela Y. Chang, Susan Horton, and Dean T. Jamison

PART 4 HEALTH SYSTEM TOPICS FROM DISEASE CONTROL PRIORITIES, THIRD EDITION

10. Quality of Care  185
    John Peabody, Riti Shimkhada, Olusoji Adeyi, Huihui Wang, Edward Broughton, and Margaret E. Kruk

11. High-Quality Diagnosis: An Essential Pathology Package  215
    Kenneth A. Fleming, Mahendra Naidoo, Michael Wilson, John Flanigan, Susan Horton, Modupe Kuti, Lai Meng Looi, Christopher P. Price, Kun Ru, Abdul Ghafur, Jinaxiang Wang, and Nestor Lago

12. Palliative Care and Pain Control  235

13. Strengthening Health Systems to Provide Emergency Care  247
    Teri A. Reynolds, Hendry Sawe, Andrés M. Rubiano, Sang Do Shin, Lee Wallis, and Charles N. Mock
14. Community Platforms for Public Health Interventions  267
   Melissa Sherry, Abdul Ghaffar, and David Bishai

15. Rehabilitation: Essential along the Continuum of Care  285
   Jody-Anne Mills, Elanie Marks, Teri Reynolds, and Alarcos Cieza

PART 5  INTERSECTORAL AND INTERNATIONAL TOPICS

16. Development Assistance for Health  299
   Eran Bendavid, Trygve Ottersen, Liu Peilong, Rachel Nugent, Nancy Paéian,
   John-Arne Rottingen, and Marco Schäferhoff

17. Pandemics: Risks, Impacts, and Mitigation  315
   Nita Madhav, Ben Oppenheim, Mark Gallivan, Prime Malembakani,
   Edward Rubin, and Nathan Wolfe

18. The Loss from Pandemic Influenza Risk  347
   Victoria Y. Fan, Dean T. Jamison, and Lawrence H. Summers

19. Fiscal Instruments for Health in India  359
   Amit Summan, Nicholas Stacey, Karen Hofman, and Ramanan Laxminarayan

DCP3 Series Acknowledgments  371
Volume Editors  373
Contributors  375
Advisory Committee to the Editors  381
Reviewers  383
Policy Forum Participants  385
Index  387
During the past 25 years, many countries have achieved significant improvements in human health and well-being. Huge problems persist, and terrible inequities must still be addressed to ease the suffering of the world’s poorest and most vulnerable. But that does not diminish several remarkable accomplishments: Since the early 1990s, the world has seen substantial reductions in extreme poverty; child and maternal mortality; and the incidence of deadly and debilitating diseases, such as tuberculosis, malaria, and HIV/AIDS. The incidence of polio has decreased by 99 percent, bringing the world to the verge of eradicating a major infectious disease for only the second time in history.

Credit for these and other advances in global health belongs to many institutions, governments, and individuals, including the scholars who organized and contributed to the first and second editions of Disease Control Priorities. We hope and expect this third edition also will have a large, salutary impact.

The first edition, DCP1, was published by the World Bank in 1993. It was the first comprehensive effort to systematically assess the effectiveness of interventions against the major diseases of low-income and middle-income countries. DCP1 also analyzed the relative costs of interventions, enabling policy makers and aid donors to make smarter decisions about how to allocate scarce health dollars for the greatest impact. DCP1 helped bring about dramatic shifts in how countries and the global community invest in health.

Indirectly, DCP1 also influenced our personal decision to devote much of our philanthropy to improving the health of people in poor countries. This came about because data from DCP1 was a basis for the World Bank’s 1993 World Development Report, which focused on investing in health and catalyzed our thinking about how and where we could make a difference. We were stunned to read that 11 million young children were dying every year from preventable causes such as pneumonia, diarrhea, malaria, and other infections that are rare or rarely fatal in the developed world. We were shocked by the disparities in health outcomes between rich countries and poorer ones. Every page screamed out that human life was not being valued as it should be.

In addition, our eyes were opened to the fact that most preventable deaths and disability in lower-income countries were caused not by hundreds of diseases but by relatively few, and that the costs of preventing and treating them were often low, relative to the benefits. Our shock turned to excitement. Here were points of leverage where we could work to reduce inequity and help realize a world where every person has the opportunity to live a healthy, productive life.

DCP2, published in 2006, again advanced the conversation on global health. Where DCP1 focused on the benefits and costs of interventions against individual diseases, contributors to DCP2 also considered how countries might gain greater traction by organizing their efforts around multi-purpose health platforms, ranging from village clinics and school-based health programs to district hospitals with emergency services and surgical units. DCP2 showed how investments in health platforms, especially for community-based primary care, could magnify impact despite limited budgets. Several countries, particularly India and Ethiopia, have pursued this approach with good results.

In important and useful ways, this third edition of Disease Control Priorities further widens the frame for discussion of health policies and priorities, innovatively addressing the different needs of countries at different stages in the development of their health systems. This edition maps out pathways—essential packages of related, cost-effective interventions—that countries can
consider to speed their progress toward universal health coverage. *DCP3* also draws attention to the catastrophically impoverishing effects that many medical procedures can have on poor families. This analysis, combined with data on the lost productivity caused by various diseases, provides insights into how investing in health, particularly in expanded access to health insurance and prepaid care, can not only save lives but also help alleviate poverty and bolster financial security.

Across the three editions, some conclusions remain constant. Childhood vaccinations, nutrition programs, access to treatment for common infections—these pay enormous returns in lives saved and suffering avoided. Family planning, maternal health programs, and gender equity benefit communities and society as a whole. Major infectious diseases can be beaten through collaborative, international efforts, as the past 25 years have shown. Overall, improving the health of the world’s most vulnerable people remains one of the best investments the global community can continue to make toward realizing a better, safer world.
Introduction

Lawrence H. Summers
Harvard University, Boston, Massachusetts, United States

Most economists pride themselves on combining social concern with hard analysis. This trait they share with an important strand of the human rights community working on global health. The late Jonathan Mann, to take a leading example, both argued for an idealistic vision of health as a human right for all and created, from almost nothing, the World Health Organization’s (WHO) effective and pragmatic Global Programme against AIDS. Paul Farmer continues to provide global leadership in advocating health as a human right, but he rightly emphasizes that advocacy alone remains insufficient. In Partners in Health, an organization Farmer cofounded with Jim Kim (now president of the World Bank), Farmer created a vehicle to go beyond advocacy and develop the practical dimensions of the aspiration to provide the highest quality of health care in rural Haiti, Rwanda, and elsewhere. In his essay “Rethinking Health and Human Rights,” Farmer points to the importance of research in this agenda: “The purpose of this research should be to do a better job of bringing the fruits of science and public health to the poorest communities” (2010, p. 456). Farmer and I may well have a different take on the contributions that have been made over time by the World Bank and other international financial institutions. But I think it fair to say that the pragmatic task of bringing technical knowledge to bear on the needs of the poor is a shared goal—and a goal that the Disease Control Priorities series has sought to advance for over two decades.

Each year the World Bank’s flagship publication, the World Development Report (WDR), attempts to assemble knowledge and to inspire action that serves the world’s poorest communities. These reports develop and take stock of research and other evidence on a specific topic to inform the World Bank’s own policies and to stimulate discourse among member countries, other development agencies, civil society, and the academic community. The WDRs are probably the world’s most widely distributed economic publication. They are prepared by the World Bank’s research arm, under the direction of its Chief Economist, a position I had the good fortune to hold in the period 1991–93. I selected health as the topic for WDR 1993.

Why health? First, health and poverty intertwine closely, and having a WDR on health provided an opportunity to provide insight into the World Bank’s central goal of reducing poverty. Second, health represents an area where governments can play a necessary and constructive role. And third, I believed that the potential gains from getting health policy right were enormous. Thus, the WDR 1993: Investing in Health, was published in June of 1993 (World Bank 1993).

Several features dominated the global health landscape at the time of the WDR 1993. First, and most visibly, the HIV/AIDS epidemic had emerged from nowhere to grow into a major problem in Africa and globally. Second, but much less visibly, government policies to control undernutrition, excess fertility, and infection had begun to bear fruit. Consolidating and expanding the scope of these successes promised enormous gains. As a consequence of success, however, China and other countries with early progress were already experiencing substantial relative growth in their older populations—and concomitant growth in the incidence of cancer, heart disease, and stroke. Intervention against these diseases is less decisive and often far more costly than intervention against infection. Policy makers thus experienced strong pressures to divert resources from high payoff infection control to responding to noncommunicable diseases.

In response to these features of the health landscape, the World Bank’s policy staff had initiated a review of
priorities for disease control. Its purpose was to identify effective yet affordable responses to the epidemics of HIV/AIDS and noncommunicable disease while expanding successes in control of childhood infection. Work began on the WDR 1993 while the priorities review was drawing to a close. The detailed analyses of value for money in that review provided strong intellectual underpinnings for the WDR 1993. Oxford University Press published the WDR 1993 and the first edition of Disease Control Priorities in Developing Countries at about the same time (Jamison, Mosley, Measham, and Bobadilla 1993; World Bank 1993).

On the occasion of the 20th anniversary of publication of the WDR 1993, The Lancet invited me to chair a commission to reassess health policies in light of two decades of remarkable change (mostly for the good) in health and related institutions around the world. Global Health 2035, the report of the Lancet Commission on Investing in Health (Jamison, Summers, and others 2013) took stock of those changes and drew policy implications for coming decades. Perhaps the most important message from Global Health 2035 is that our generation, uniquely in history, has the resources and knowledge to close most of the enormous health gap between rich and poor within a generation. The work of the Lancet Commission provided a policy framework for this concluding volume of the third edition of Disease Control Priorities (DCP3). For evidence-oriented decision makers in ministries and in development agencies, and for a broader community, the DCP series has provided (as it did for Global Health 2035) a wealth of information relevant to informing policies for improving health and reducing health-related poverty.

Let me close by placing DCP3 into a context not just of health policy formulation but also of macroeconomic policy formulation. Macroeconomic policy encompasses three major components:

• Establishing and enforcing an environment for secure and inclusive economic growth. Creating this environment includes finance of domestic and international security, enforcement of contracts and property rights, regulation of cross border flows (goods and services, capital, persons), and establishing the broad structure and regulation of the financial system. Global warming and the risk of severe pandemics pose particular challenges to long-term economic growth. In chapter 18 of this volume, I report work undertaken with several colleagues that assesses the magnitude of pandemic influenza risk (Fan, Jamison, and Summers 2018). Suffice it to say that low probability but potentially devastating pandemics pose a global risk—but particularly a risk to lower-income countries—that warrants inclusion on the macroeconomic policy agenda.

• Establishing mechanisms for social insurance—insurance that enables income security in old age; that provides a financial safety net against permanent disability, against transitory job loss, and against inadequate earning power; and that provides financial protection against medical expenses. DCP3’s extended cost-effectiveness analysis introduces an approach to efficient purchase of financial protection against medical expenses.

• Allocation of resources within and across those sectors where efficient levels of investment require substantial public finance. These sectors include much of physical infrastructure, research, education, environmental protection and population health.

DCP3’s methods and conclusions provide critical guidance on resource allocation to and within the health sector. Spending the resources available for health investments on the wrong interventions is worse than inefficient: it costs lives. As DCP3’s findings make clear, huge variation remains in how many lives can be saved from a million dollars spent on different interventions. Transferring resources from low- to high-yield health interventions is, therefore, a moral imperative. Nor should resources available to the health sector be taken as given. Careful consideration of the social returns to increasing the health sector’s share of national budgets and of national income suggests that, in many countries, macroeconomic policy makers underinvest in health.

My own career has centered on macroeconomic policy and on research to improve macroeconomic policy. Over the years I have increasingly come to feel that getting health policy right contributes importantly to improving the social insurance and public sector investment dimensions of macroeconomic policy. For this reason, I have closely followed the 20-year evolution of the disease control priorities agenda. This new edition continues DCP’s tradition of informing the efficient selection of health interventions. And it extends that agenda to informing choices where health policy can contribute to poverty reduction as well as health improvement.

REFERENCES


Preface

Budgets constrain choices. Policy analysis helps decision makers achieve the greatest value from limited available resources. In 1993, the World Bank published *Disease Control Priorities in Developing Countries* (DCP1), an attempt to systematically assess the cost-effectiveness (value for money) of interventions that would address the major sources of disease burden in low- and middle-income countries (LMICs). The World Bank’s 1993 *World Development Report* on health drew heavily on DCP1’s findings to conclude that specific interventions against noncommunicable diseases were cost-effective, even in environments where high burdens of infection and undernutrition remained top priorities.

DCP2, published in 2006, updated and extended DCP1 in several aspects, including explicit consideration of the implications for health systems of expanded intervention coverage. One way health systems expand coverage is through selected platforms that deliver interventions that require similar logistics but address heterogeneous health problems. Platforms often provide a more natural unit for investment than do individual interventions. Analysis of the costs of providing platforms—and of the health improvements they can generate in given epidemiological environments—can help to guide health system investments and development.

DCP3 differs importantly from DCP1 and DCP2 by extending and consolidating the concepts of platforms and by offering explicit consideration of the financial risk protection objective of health systems. In populations lacking access to health insurance or prepaid care, medical expenses that are high relative to income can be impoverishing. Where incomes are low, seemingly inexpensive medical procedures can have catastrophic financial effects. DCP3 offers an approach (extended cost-effectiveness analysis, or ECEA) to explicitly include financial protection as well as the distribution across income groups of financial and health outcomes resulting from policies (for example, public finance) to increase intervention uptake. DCP3 provides interested policymakers with evidenced-based findings on financial as well as health interventions to assist with resource allocation.

This volume of DCP3, volume 9, places the findings from the first eight volumes into a framework identifying an efficient pathway toward essential universal health coverage (EUHC) through the identification of 21 essential packages that include health interventions, and fiscal and intersectoral policies. The intervention packages are defined by groups with common professional interests (for example, child health or surgery) and include interventions delivered across a range of platforms. The volume also provides an up-to-date summary of levels and trends in deaths by cause and an early attempt to assess which elements of disease burden most contribute to impoverishment. While most of DCP3’s 21 packages of interventions are developed in the first eight volumes, several of the packages are presented here, including discussion of pandemic...
preparedness. Along with these new elements, DCP3 updates the efforts of DCP1 and DCP2 to synthesize cost-effectiveness analysis of health interventions.

The overall convergence of many countries and international development partners around the UN Global Goals for 2030 has raised in particular the need for careful analytic work that informs priorities and choices. DCP3 stands unique in taking on this challenge, providing analyses of the contributions of 218 health system interventions and 71 intersectoral policies grouped into 21 essential packages.

DCP3 is a large-scale enterprise involving an international community of authors, editors, peer reviewers, and research and staff assistants who contributed their time and expertise to the preparation and completion of this series. We convey our acknowledgements elsewhere in this volume. Here we express our particular gratitude to the Bill & Melinda Gates Foundation for its sustained financial support, to the University of Washington's Department of Global Health for hosting DCP3’s Secretariat, and to the World Bank, the original home for the DCP series and accomplished publisher of its products.

Dean T. Jamison
Hellen Gelband
Sue Horton
Prabhat Jha
Ramanan Laxminarayan
Charles N. Mock
Rachel Nugent
Abbreviations

ACE  Advisory Committee to the Editors
AIDS  acquired immune deficiency virus
ANM  auxiliary nurse midwifery
ARI  acute respiratory illness
ART  antiretroviral therapy
BCA  benefit-cost analysis
BMI  body mass index
CCT  conditional cash transfer
CEA  cost-effectiveness analysis
CEPI  Coalition for Epidemic Preparedness Innovations
CHE  catastrophic health expenditure
CHWs  community health workers
CLAS  local health administration communities
COPD  chronic obstructive pulmonary disease
CPD  continuing professional development
CRS  Creditor Reporting System
CVD  cardiovascular disease
DAC  Development Assistance Committee
DALY  disability-adjusted life year
DCP2 Disease Control Priorities in Developing Countries (second edition)
DCP3 Disease Control Priorities (third edition)
DOTs  directly observed treatment, short course
ECEA  extended cost-effectiveness analysis
EP  essential package
EPHF  Essential Public Health Functions
EQA  external quality assurance
EUHC  essential universal health coverage
FRP  financial risk protection
FTE  full-time equivalent
Gavi  Gavi, the Vaccine Alliance
GBD  global burden of disease
GBHS  global burden of health-related suffering
GDP  gross domestic product
GHE | Global Health Estimates
---|---
GST | goods and services tax
HICs | high-income countries
HIV | human immunodeficiency virus
HIV/AIDS | human immunodeficiency virus/acquired immune deficiency syndrome
HPP | highest-priority package
IAMP | Interacademy Medical Panel
ICD | International Classification of Diseases
ICER | incremental cost-effectiveness ratio
ICU | intensive care unit
IHD | ischemic heart disease
IHME | Institute of Health Metrics and Evaluation
IHR | International Health Regulations
INEGI | National Institute of Statistics and Geography (Mexico)
IPCC | Intergovernmental Panel on Climate Change
LC-GAPCPC | *The Lancet* Commission on Global Access to Palliative Care and Pain Control
LICs | low-income countries
LIS | laboratory information systems
LMICs | low- and middle-income countries
LPG | liquefied petroleum gas
MDGs | Millennium Development Goals
MERS | Middle East respiratory syndrome
MICs | middle-income countries
MTB/RIF | mycobacterium tuberculosis/rifampicin
NAM | National Academy of Medicine
NCDs | noncommunicable diseases
NCEF | National Clean Energy Fund
NGO | nongovernmental organization
NTCP | National Tobacco Control Programme
NTDs | neglected tropical diseases
ODA | official development assistance
OECD | Organisation for Economic Co-operation and Development
OOP | out of pocket
P4P | pay for performance
PDS | public distribution system
PEF | Pandemic Emergency Financing Facility
PEPFAR | U.S. President’s Emergency Plan for AIDS Relief
POCT | point-of-care testing
PPA | public-private alliance
PPP | purchasing power parity
PT | proficiency testing
QALYs | quality-adjusted life years
QIDS | Quality Improvement Demonstration Study
RBF | results-based financing
R&D | research and development
RNTCP | Revised National Tuberculosis Control Program
SARA | Service Availability and Readiness Assessment
SARS | severe acute respiratory syndrome